TITLE

Hepatotoxicity of Rifampin-Pyrazinamide and Isoniazid Preventive Therapy and Tuberculosis Treatment

AUTHOR(S)
van Hest, Rob; Baars, Hennie; Kik, Sandra; van Gerven, Paul; Trompenaars, Marie-Christine; Kalisvaart, Nico; Keizer, Sytze; Borgdorff, Martien; Mensen, Marlies; Cobelens, Frank
PUB. DATE
August 2004
SOURCE
Clinical Infectious Diseases;8/15/2004, Vol. 39 Issue 4, p488
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Severe liver injury has been attributed to preventive treatment of latent tuberculosis infection with a 2-month course of rifampin-pyrazinamide. Methods. A retrospective cohort study in The Netherlands compared the hepatotoxicity of preventive treatment with rifampin-pyrazinamide with that of preventive treatment with isoniazid, and also with that of treatment for active tuberculosis containing at least isoniazid, rifampin, and pyrazinamide. Results. Preventive treatment with rifampin-pyrazinamide caused severe hepatotoxicity more often than did preventive treatment with isoniazid (odds ratio [OR], 2.61; 95% confidence interval [CI], 1.26-5.39; P = .012), especially in patients <25 years old. it also caused severe hepatotoxicity more often than triple- or quadruple-drug tuberculosis treatment (OR, 2.61; 95% CI, 1.2 1-5.59; P = .016), especially if the pyrazinamide dose was ≥30 mg/kg. Preventive treatment with rifampin-pyrazinamide was more hepatotoxic even when the advised pyrazinamide dose of up to 20 mg/kg for preventive treatment was compared with the pyrazinamide dose of 30 mg/kg for tuberculosis treatment. Conclusions. Preventive treatment with rifampin-pyrazinamide causes severe hepatotoxicity more often than does preventive treatment with isoniazid or curative treatment for tuberculosis.
ACCESSION #
14048040

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics